Related Experiment Video
Updated: Nov 5, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Recurrent episodes of palpable migratory arciform erythema associated with IVIg infusions
Nathan Johnson1, Patrick Rush, Alex Holliday
1Section of Dermatology, Department of Internal Medicine, Virginia Tech Carilion School of Medicine and Carilion Clinic, Roanoke, VA. nmjohnson@carilionclinic.org.
Abstract:
Palpable migratory arciform erythema (PMAE) is an uncommon T cell pseudolymphoma characterized by erythematous, annular-to-arciform papules and plaques. Although the eruption is self-limited in most cases, recurrences are routine. Diagnosis requires attention to clinical history as well as histopathologic analysis, which allow for differentiation from other T cell pseudolymphomas and gyrate erythemas. A common triggering factor has not been identified. We report a 60-year-old man who developed PMAE after IVIg infusion. Interestingly, although the individual eruptions were self-limited and resolved after several weeks, subsequent infusions predictably resulted in recurrence of PMAE, confirming the association. To our knowledge, this is the first reported case of recurrent PMAE in association with IVIg infusions.
Insights
Palpable migratory arciform erythema (PMAE), a rare T cell pseudolymphoma, can be triggered by IVIg infusions. This case highlights recurrent PMAE following IVIg, suggesting a potential association.
Area of Science:
- Dermatology
- Immunology
- Pathology
Background:
- Palpable migratory arciform erythema (PMAE) is an uncommon T cell pseudolymphoma.
- PMAE presents as erythematous, annular-to-arciform papules and plaques.
- While typically self-limited, PMAE often recurs, and triggers are not well-established.
Purpose of the Study:
- To report a case of recurrent PMAE.
- To investigate the potential association between IVIg infusions and PMAE development.
- To contribute to the understanding of PMAE triggers.
Main Methods:
- Clinical case presentation of a 60-year-old male patient.
- Detailed observation of skin eruption following IVIg infusion.
- Histopathologic analysis for diagnostic confirmation.
Main Results:
- The patient developed recurrent PMAE after IVIg infusions.
- Each episode of PMAE was self-limited, resolving within weeks.
- Subsequent IVIg infusions consistently triggered the recurrence of PMAE.
Conclusions:
- IVIg infusion is identified as a potential trigger for recurrent PMAE.
- This is the first reported case linking IVIg infusions to recurrent PMAE.
- Further investigation into IVIg as a PMAE trigger is warranted.
Related Concept Videos
Endocarditis II: Clinical Features of Infective Endocarditis
Allergic Drug Reactions
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Nephrotic Syndrome II : Assessment and Medical Management
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Allergic Reactions

